Literature DB >> 21968965

Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.

Munehiro Yoshino1, Hiroki Yagura, Hiroyuki Kushida, Hitoshi Yonemoto, Hiroki Bando, Yoshihiko Ogawa, Keishiro Yajima, Daisuke Kasai, Tomohiro Taniguchi, Dai Watanabe, Yasuharu Nishida, Takeshi Kuwahara, Tomoko Uehira, Takuma Shirasaka.   

Abstract

Impaired renal function caused by tenofovir disoproxil fumarate (TDF) is considered reversible by discontinuing TDF administration, but there are occasional cases of incomplete recovery. We investigated the recovery of renal function after the discontinuation of TDF. Subjects comprised patients who had been started on TDF but in whom it was later discontinued because of impaired renal function. We investigated renal function until 96 weeks after the discontinuation of TDF, and the duration of TDF administration, up to May 2010. TDF was discontinued because of impaired renal function in 21 of 766 patients (2.7%). Following discontinuation, a significant recovery was seen in eGFR (p = 0.003). The median duration of administration was 28 days (6-941 days) in 9 patients whose eGFR recovered to pre-administration levels, 405 days (250-1,379) in 7 patients in whom mild recovery was seen, and 1,110 days (421-1,470) in 5 patients in whom eGFR was much lower than at the time of discontinuation. A significant correlation was seen between the eGFR recovery rate and the duration of TDF administration. TDF administration was discontinued because of renal impairment in 2.7% of patients. The duration of TDF administration was short in patients whose renal function recovered to pre-administration levels, but patients in whom sufficient recovery was not seen after discontinuation had received TDF over long periods and included many whose renal function gradually declined, even after discontinuation. Recovery of renal function after discontinuation of TDF is likely affected by the duration of TDF administration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21968965     DOI: 10.1007/s10156-011-0310-6

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  4 in total

1.  Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.

Authors:  Samir K Gupta; Albert M Anderson; Ramin Ebrahimi; Todd Fralich; Hiba Graham; Valeska Scharen-Guivel; John F Flaherty; Claude Fortin; Robert C Kalayjian; Anita Rachlis; Christina M Wyatt
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

2.  Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.

Authors:  Giuseppe Lapadula; Davide Paolo Bernasconi; Salvatore Casari; Franco Maggiolo; Roberto Cauda; Massimo Di Pietro; Nicoletta Ladisa; Laura Sighinolfi; Sarah Dal Zoppo; Francesca Sabbatini; Alessandro Soria; Chiara Pezzoli; Annalisa Mondi; Silvia Costarelli; Maria Grazia Valsecchi; Carlo Torti; Andrea Gori
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

3.  Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

Authors:  Sophie Jose; Lisa Hamzah; Lucy J Campbell; Teresa Hill; Martin Fisher; Clifford Leen; Richard Gilson; John Walsh; Mark Nelson; Phillip Hay; Margaret Johnson; David Chadwick; Dorothea Nitsch; Rachael Jones; Caroline A Sabin; Frank A Post
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

4.  Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.

Authors:  Kensuke Abe; Taku Obara; Satomi Kamio; Asahi Kondo; Junji Imamura; Tatsuya Goto; Toshihiro Ito; Hiroshi Sato; Nobuyuki Takahashi
Journal:  AIDS Res Ther       Date:  2021-12-07       Impact factor: 2.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.